secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001171843-25-005992
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study
------------------------------------------------------------------

- Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.
- Final $1.4M advance received under prior June 2025 facility, totaling $8.5M from that agreement.
- Loan is a related-party transaction; Aptose relies on financial hardship exemption from formal valuation and minority approval.
- Proceeds fund TUSCANY Phase 1/2 trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML patients.
- Early data showed 9/10 patients responded; 100% CR/CRh at 80mg and 120mg cohorts across adverse mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005992/0001171843-25-005992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005992/f8k_092225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer